A new era in TAVI: key recommendations from the 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease

This video is offered by Edwards Lifesciences

Summary

Bernard Prendergast, UK, shares key recommendations from the 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease, amongst them the continued endorsement of the practice of the Heart Team, new international randomised controlled trials demonstrating the effectiveness of TAVI in intermediate-risk patients, and long-term follow-up of these patients to be shared by all members of the Heart Team.

TAVI is now a mature technology that will become the dominant treatment for aortic stenosis in the very near future, and will require a change in the patient referral pathway from cardiac surgeon to cardiologist. It will also pose a challenge: as the number of patients eligible for TAVI is set to triple to quadruple within the next 5 years, programmes already saturated in many centres will be under pressure, and extended training will be needed for the next generation of interventional cardiologists.